Scholar Rock Holding (SRRK) Depreciation & Amortization (CF) (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Depreciation & Amortization (CF) of $335000.0 for Q1 2026, down 14.76% year-over-year from $393000.0 in Q1 2025, and down 21.18% quarter-over-quarter from $425000.0 in Q4 2025.
Powered by 
Analysis
Scholar Rock Holding (SRRK) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $335000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 14.76% year-over-year to $335000.0; the TTM figure through Mar 2026 stood at $1.6 million (down 5.72% YoY), while the FY2025 annual figure was $1.7 million, down 12.74% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $335000.0, down from $425000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $763000.0 in Q4 2022, with the low at $335000.0 in Q1 2026.
- The 5-year median for Depreciation & Amortization (CF) is $598000.0 (2024), against an average of $572882.4.
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) climbed 26.95% in 2022, then tumbled 46.73% in 2024.
- Scholar Rock Holding's Depreciation & Amortization (CF) stood at $763000.0 in 2022, then retreated by 11.93% to $672000.0 in 2023, then sank by 46.73% to $358000.0 in 2024, then advanced by 18.72% to $425000.0 in 2025, then retreated by 21.18% to $335000.0 in 2026.
- Business Quant data shows SRRK's Depreciation & Amortization (CF) at $335000.0 in Q1 2026, $425000.0 in Q4 2025, and $423000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Scholar Rock Holding | 7.24 Bn | 7.24 Bn | - | 297,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 297,000.00 |
| Mar 31, 2026 | 335,000.00 |
| Dec 31, 2025 | 467,000.00 |
| Sep 30, 2025 | 423,000.00 |
| Jun 30, 2025 | 417,000.00 |
| Mar 31, 2025 | 393,000.00 |
| Dec 31, 2024 | 395,000.00 |
| Sep 30, 2024 | 446,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 598,000.00 |
| Dec 31, 2023 | 672,000.00 |
| Sep 30, 2023 | 708,000.00 |
| Jun 30, 2023 | 731,000.00 |
| Mar 31, 2023 | 733,000.00 |
| Dec 31, 2022 | 763,000.00 |
| Sep 30, 2022 | 744,000.00 |
| Jun 30, 2022 | 744,000.00 |
| Mar 31, 2022 | 749,000.00 |
| Dec 31, 2021 | 727,000.00 |
| Sep 30, 2021 | 673,000.00 |